Headlines

AskBio, a subsidiary of Bayer (BAYN GY), announces FDA acceptance of a IND application for AB-1009 gene therapy being developed for the treatment of late-onset Pompe disease

Newsquawk Staff ·

AskBio, a subsidiary of Bayer (BAYN GY), announces FDA acceptance of a IND application for AB-1009 gene therapy being developed for the treatment of late-onset Pompe disease.

What it means

AskBio's announcement regarding the FDA's acceptance of its IND application for AB-1009 signals a positive step in Bayer's investment in innovative gene therapies. This could enhance Bayer's positioning in the biotechnology sector and may generate investor interest, especially if the product progresses successfully, potentially impacting share performance in the pharmaceuticals space.

Sources

Related headlines